ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention

Julie H. Ostrander, Joseph C. Baker, Siya Lem, Gloria Broadwater, Gregory R. Bean, Nicholas C. D'Amato, Vanessa K. Goldenberg, Craig Rowell, Catherine Ibarra-Drendall, Tracey Grant, Patrick G. Pilie, Shauna N. Vasilatos, Michelle M. Troch, Victoria Scott, Lee G. Wilke, Carolyn Paisie, Sarah M. Rabiner, Alejandro Torres-Hernandez, Carola M. Zalles, Victoria L. Seewaldt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

Original languageEnglish (US)
Pages (from-to)1884-1890
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Chemoprevention
Tamoxifen
Estrogen Receptors
Breast
Fine Needle Biopsy
Research Design
Biomarkers
Immunohistochemistry
Breast Neoplasms

Cite this

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. / Ostrander, Julie H.; Baker, Joseph C.; Lem, Siya; Broadwater, Gloria; Bean, Gregory R.; D'Amato, Nicholas C.; Goldenberg, Vanessa K.; Rowell, Craig; Ibarra-Drendall, Catherine; Grant, Tracey; Pilie, Patrick G.; Vasilatos, Shauna N.; Troch, Michelle M.; Scott, Victoria; Wilke, Lee G.; Paisie, Carolyn; Rabiner, Sarah M.; Torres-Hernandez, Alejandro; Zalles, Carola M.; Seewaldt, Victoria L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 8, 01.08.2008, p. 1884-1890.

Research output: Contribution to journalArticle

Ostrander, JH, Baker, JC, Lem, S, Broadwater, G, Bean, GR, D'Amato, NC, Goldenberg, VK, Rowell, C, Ibarra-Drendall, C, Grant, T, Pilie, PG, Vasilatos, SN, Troch, MM, Scott, V, Wilke, LG, Paisie, C, Rabiner, SM, Torres-Hernandez, A, Zalles, CM & Seewaldt, VL 2008, 'ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention', Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 8, pp. 1884-1890. https://doi.org/10.1158/1055-9965.EPI-07-2696
Ostrander, Julie H. ; Baker, Joseph C. ; Lem, Siya ; Broadwater, Gloria ; Bean, Gregory R. ; D'Amato, Nicholas C. ; Goldenberg, Vanessa K. ; Rowell, Craig ; Ibarra-Drendall, Catherine ; Grant, Tracey ; Pilie, Patrick G. ; Vasilatos, Shauna N. ; Troch, Michelle M. ; Scott, Victoria ; Wilke, Lee G. ; Paisie, Carolyn ; Rabiner, Sarah M. ; Torres-Hernandez, Alejandro ; Zalles, Carola M. ; Seewaldt, Victoria L. / ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 8. pp. 1884-1890.
@article{8618a5f913a14efeb12bd66e6b58b4b2,
title = "ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention",
abstract = "Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.",
author = "Ostrander, {Julie H.} and Baker, {Joseph C.} and Siya Lem and Gloria Broadwater and Bean, {Gregory R.} and D'Amato, {Nicholas C.} and Goldenberg, {Vanessa K.} and Craig Rowell and Catherine Ibarra-Drendall and Tracey Grant and Pilie, {Patrick G.} and Vasilatos, {Shauna N.} and Troch, {Michelle M.} and Victoria Scott and Wilke, {Lee G.} and Carolyn Paisie and Rabiner, {Sarah M.} and Alejandro Torres-Hernandez and Zalles, {Carola M.} and Seewaldt, {Victoria L.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1158/1055-9965.EPI-07-2696",
language = "English (US)",
volume = "17",
pages = "1884--1890",
journal = "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention

AU - Ostrander, Julie H.

AU - Baker, Joseph C.

AU - Lem, Siya

AU - Broadwater, Gloria

AU - Bean, Gregory R.

AU - D'Amato, Nicholas C.

AU - Goldenberg, Vanessa K.

AU - Rowell, Craig

AU - Ibarra-Drendall, Catherine

AU - Grant, Tracey

AU - Pilie, Patrick G.

AU - Vasilatos, Shauna N.

AU - Troch, Michelle M.

AU - Scott, Victoria

AU - Wilke, Lee G.

AU - Paisie, Carolyn

AU - Rabiner, Sarah M.

AU - Torres-Hernandez, Alejandro

AU - Zalles, Carola M.

AU - Seewaldt, Victoria L.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

AB - Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

UR - http://www.scopus.com/inward/record.url?scp=54049132594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049132594&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-07-2696

DO - 10.1158/1055-9965.EPI-07-2696

M3 - Article

C2 - 18708376

AN - SCOPUS:54049132594

VL - 17

SP - 1884

EP - 1890

JO - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

SN - 1055-9965

IS - 8

ER -